Adamas Pharmaceuticals, Inc. (ADMS) Swings to Q1 Loss
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Join SI Premium – FREE
Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) reported Q1 EPS of ($0.67), versus $1.70 reported last year. Revenue for the quarter came in at $176 thousand, versus $30.6 million reported last year.
For earnings history and earnings-related data on Adamas Pharmaceuticals, Inc. (ADMS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
- Faraday Future stockholders approve $25M private placement proposal
- Goldman Sachs Upgrades Tingyi Cayman Islands Holding Corp. (322:HK) (TCYMY) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
